



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 06/26/2019 07:05
Last Report Issued 03/22/2019 14:16

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 8030SP-POS
Patient ID 8030SP-POS
Chain 19000491
Age Not Given DOB Not Given
Gender Not Given
Workorder 19000491
Received 03/19/2019 12:13

Sample ID 19000491-001
Matrix Serum or Plasma
Patient Name 8030SP-POS
Patient ID 8030SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains data for Cannabinoids, Barbiturates, Ethanol, and Methanol.

Results for sample 19000491-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 19000491-001
Matrix Serum or Plasma
Patient Name 8030SP-POS
Patient ID 8030SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains data for Isopropanol and Acetone, including analysis by Gas Chromatography/Mass Spectrometry (GC/MS).

Results for sample 19000491-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 19000491-001
Matrix Serum or Plasma
Patient Name 8030SP-POS
Patient ID 8030SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

Following an oral dose of 4.5 g, peak plasma concentrations averaged 90 mcg/mL approximately 50 minutes after administration. GHB has a terminal half-life of 0.5 to 1 hour.

The following effects have been generally associated with the corresponding blood concentrations:
>260 mcg/mL: Deep sleep/coma
150 - 260 mcg/mL: Moderate sleep
52 - 150 mcg/mL: Light sleep
< 52 mcg/mL: Wakefulness
Responses are variable and may differ even within the same individual.
The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.

Analysis by High Performance Liquid Chromatography/Time of Flight-Mass Spectrometry (LC/TOF-MS)

MDMA	See Comment	ng/mL	10	
------	-------------	-------	----	--

Synonym(s): 3,4-Methylenedioxymethamphetamine; Ecstasy
Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).

Scope Statement See Comment

Comment: The following is a general list of compound classes included in this screen. The detection of any specific analyte is concentration-dependent. Note, not all known analytes in each specified compound class are included. Some specific analytes outside these classes are also included. For a detailed list of all analytes and reporting limits, please contact NMS Labs.

Amphetamines, Anticonvulsants, Antidepressants, Antihistamines, Antipsychotic Agents, Benzodiazepines, CNS Stimulants, Cocaine and Metabolites, Hallucinogens, Hyposedatives, Hypoglycemics, Muscle Relaxants, Non-Steroidal Anti-Inflammatory Agents, Opiates and Opioids.

52250SP Alcohols and Acetone Confirmation, Serum/Plasma

Analysis by Headspace Gas Chromatography (GC)

Results for sample 19000491-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
 Phone: (215) 657-4900 Fax: (215) 657-2972
 e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 19000491-001
Matrix Serum or Plasma
Patient Name 8030SP-POS
Patient ID 8030SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Ethanol Synonym(s): Ethyl Alcohol	Confirmed	mg/dL	10	
Methanol Synonym(s): Methyl Alcohol	Confirmed	mg/dL	5.0	
Isopropanol Synonym(s): Isopropyl Alcohol	Confirmed	mg/dL	5.0	
Acetone	Confirmed	mg/dL	5.0	
52491SP Amphetamines Confirmation, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Amphetamine Amphetamine is a drug as well as the metabolite of Methamphetamine. Therapeutic Range (treatment of Narcolepsy or Attention Deficit Disorder) with doses between 10 and 30 mg daily: Mean peak plasma concentrations between 35 and 110 ng/mL.	50	ng/mL	5.0	
Methamphetamine Benzphetamine is rapidly metabolized to Amphetamine and Methamphetamine. This test reports Methamphetamine as the total of the undifferentiated d and l enantiomers. The ratio of these enantiomers is important in determining whether the source of Methamphetamine is from over the counter medications, prescribed medication or controlled substances. Call lab for further information on d to l enantiomer ratio determination.	50	ng/mL	5.0	
MDA Synonym(s): 3,4-Methylenedioxyamphetamine; Adam; MDMA Metabolite	50	ng/mL	5.0	

Results for sample 19000491-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 19000491-001
Matrix Serum or Plasma
Patient Name 8030SP-POS
Patient ID 8030SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
<p>MDA is a metabolite of MDMA and methylenedioxyethylamphetamine (MDEA) and is abused for its central nervous system stimulant and hallucinogenic properties. The peak concentration of the MDA metabolite following a 110 mg dose of MDMA was reported as 28 ng/mL at 4 hours.</p>				
<p>MDMA</p>	50	ng/mL	5.0	
<p>Synonym(s): 3,4-Methylenedioxyamphetamine; Adam; MDMA Metabolite</p> <p>MDA is a metabolite of MDMA and methylenedioxyethylamphetamine (MDEA) and is abused for its central nervous system stimulant and hallucinogenic properties. The peak concentration of the MDA metabolite following a 110 mg dose of MDMA was reported as 28 ng/mL at 4 hours.</p>				